Uh-Oh, Merck: FDA Approves Cheaper Versions of Singulair

Ten drug makers can market generic versions of the best-selling drug


Uh-Oh, Merck: FDA Approves Cheaper Versions of Singulair

Drug maker Merck (NYSE:MRK) is about to see roughly two-thirds of sales for one of its most popular medications disappear.

On Friday, the Food and Drug Administration (FDA) gave the okay to ten pharmaceutical makers to sell generic forms of Merck’s asthma drug, Singulair, Reuters noted.

prescription drugs 200x200 Uh Oh, Merck: FDA Approves Cheaper Versions of Singulair
Merck Could Have a Home Run in Sight

Merck’s patent exclusivity on Singulair, which generates $5 billion in annual sales for the company, expired this year.

Among the manufacturers awarded permission to make generic versions of Singulair are Teva Pharmaceuticals (NYSE:TEVA), Novartis (NYSE:NVS) and Mylan (NASDAQ:MYL).

In order to compensate for the projected losses in Singulair sales, Merck is scrambling to develop new drugs. The company will apply for FDA approval on six new drugs over the coming year and a half.

Shares of Merck moved up fractionally in Monday morning trading.

Article printed from InvestorPlace Media, http://investorplace.com/2012/08/uh-oh-merck-fda-approves-cheaper-versions-of-singulair/.

©2015 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.